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The signal transduction pathway wherein mTOR
regulates cellular growth and proliferation is an
active target for drug discovery. The search for new
mTOR inhibitors has recently yielded a handful of
promising compounds that hold therapeutic poten-
tial. This search has been limited by the lack of a
high-throughput assay to monitor the phosphoryla-
tion of a direct rapamycin-sensitive mTOR substrate
in cells. Here we describe a novel cell-based chemi-
cal genetic screen useful for efficiently monitoring
mTOR signaling to 4E-BPs in response to stimuli.
The screen is based on the nuclear accumulation of
eIF4E, which occurs in a 4E-BP-dependent manner
specifically upon inhibition of mTOR signaling. Using
this assay in a small-scale screen, we have identified
several compounds not previously known to inhibit
mTOR signaling, demonstrating that this method
can be adapted to larger screens.INTRODUCTION
Themammalian target of rapamycin (mTOR) is a key integrator of
multiple intracellular and extracellular cues regulating cell growth
and proliferation. Enhanced progrowth mTOR signaling is often
seen in cancer resulting from mutations of upstream regulators
(e.g., PI3K, PTEN, STK11/LKB1, and TSC2), which uncouple
mTOR from environmental cues (Choo and Blenis, 2006; Furic
et al., 2009). Consequently, it has been proposed that cancers
driven by mTOR signaling would be particularly sensitive to
mTOR inhibitory compounds, and as such rapamycin analogs
are used in the clinic as anticancer agents (Abraham and Eng,
2008; Choo and Blenis, 2006; Weinstein, 2002).
Rapamycin inhibits mTOR signaling by simultaneously binding
to FKBP12 and to the FKBP12-rapamycin binding (FRB) domain
of mTOR. mTOR exists in two functionally distinct complexes:
the rapamycin-sensitive mTOR complex 1 (mTORC1) and the
rapamycin-insensitive mTOR complex 2 (mTORC2) (Loewith
et al., 2002; Sarbassov et al., 2004). Recent studies suggested
that mTORC1 itself exhibits both rapamycin-sensitive and rapa-
mycin-insensitive activities (Feldman et al., 2009; Thoreen et al.,
2009). mTORC1 regulates mRNA translation and cell growth via
phosphorylation of the eIF4E binding proteins (4E-BPs) 4E-BP1,1240 Chemistry & Biology 16, 1240–1249, December 24, 2009 ª20094E-BP2, and 4E-BP3, and of the ribosomal protein S6 (rpS6)
kinases, S6K1 and S6K2. The latter belong to the AGC kinase
family, together with Akt, various PKC isoforms, and SGK
(Mora et al., 2004; Peterson and Schreiber, 1999). Most data
support a model whereby mTORC1 phosphorylates 4E-BPs
and the hydrophobic motif site on S6K1 and S6K2, whereas
mTORC2 is the in vivo kinase for the corresponding site of
other key AGC kinase family members (Garcia-Martinez and
Alessi, 2008; Hresko and Mueckler, 2005; Ikenoue et al., 2008;
Sarbassov et al., 2005). Given the importance of these rapamy-
cin-insensitive mTOR substrates, it has been proposed that non-
rapamycin mTOR inhibitors may more potently target mTOR-
dependent tumors (Edinger et al., 2003; Sabatini, 2006).
The mechanism by which rapamycin specifically inhibits
mTORC1 and not mTORC2 remains elusive. Different theories
include (a) an inability of rapamycin to bind mTORC2, possibly
due to mTOR’s binding partner rictor forming a physical barrier
(Jacinto et al., 2004; Sarbassov et al., 2004), (b) the ability of rapa-
mycin to prevent mTOR:raptor complex formation or even to
dissociate existing complexes (Hara et al., 2002; Kim et al.,
2002; Oshiro et al., 2004), and (c) an mTORC1-specific ability of
rapamycin to compete with phosphatidic acid (Toschi et al.,
2009). Identification of additional agents that modulate mTORC1
and not mTORC2 activity will facilitate our understanding of
this differential mTORC1 versus mTORC2 regulation, and sug-
gest novel inhibitory strategies. The approval of the rapamycin
analogs CCI-779 andRAD001 for treatment of patients with renal
cell carcinoma is quite promising (Abraham and Eng, 2008).
However, because rapamycin treatment can lead to the activa-
tion of prosurvival signaling through mTORC2 and Akt (Wan
et al., 2007), the tolerance of some cancers to these agents has
been postulated to be caused by the inability to target both the
mTORC1 and mTORC2 complexes (Rosen and She, 2006).
Multiple ATP-competitive mTOR kinase domain inhibitors have
been described in the literature that are capable of blocking
both mTORC1 and mTORC2 activities (Ballou et al., 2007; Fan
et al., 2006; Feldman et al., 2009; Maira et al., 2008; Thoreen
et al., 2009). In general, these compounds represent modifica-
tions of known PI-3 kinase (PI3K) and PI3K-like kinase (PIKK)
inhibitors (Knight et al., 2006), and a limited number of published
reports describe more diverse compound library screens
(Thoreen et al., 2009; Yang et al., 2007; Yu et al., 2009), due
possibly to the cumbersome bacterial expression of the relatively
large PIKKs. Therefore, cell-based assays using known in vivo
substrates will most likely continue to be the preferred screening
method for PIKKs (Fan et al., 2007; Livingstone et al., 2005).Elsevier Ltd All rights reserved
Chemistry & Biology
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is used as an endpoint is restricted by the availability of suitable
antibodies to such phosphoproteins. The phosphoprotein
biomarker for mTORC1 signaling, rpS6, also reflects inhibition
of S6K1 and non-mTOR inputs to this kinase, whereas anti-
bodies recognizing direct substrates of mTOR (S6K1 and 4E-
BP1) have largely proven unsuitable for immunostaining experi-
ments (Engelman et al., 2008; Guertin et al., 2009). Alternative
approaches are thus required to monitor mTOR substrate phos-
phorylation in vivo.
Eukaryotic initiation factor (eIF) 4E, the mRNA 50 cap-binding
protein, is a key regulator of mRNA translation in the cytoplasm,
and the activity of eIF4E is repressed by 4E-BPs. Binding of the
4E-BPs to eIF4E is controlled by the mTOR-dependent phos-
phorylation of 4E-BPs (Gingras et al., 1998; Pause et al., 1994)
such that the hypophosphorylated forms of 4E-BPs bind to
eIF4E and prevent interaction of eIF4Ewith eIF4G, thus impairing
cap-dependent translation (Haghighat et al., 1995). Conversely,
in cells with strongmTOR signaling, 4E-BPs become hyperphos-
phorylated, releasing eIF4E from 4E-BPs for interaction with
eIF4G and assembly into the eIF4F complex. Whereas eIF4E is
predominantly cytoplasmic in mammalian cells, nuclear eIF4E
has been observed using biochemical fractionation and immu-
nofluorescence analyses (Dostie et al., 2000; Lang et al., 1994;
Lejbkowicz et al., 1992), and serum starvation induces an accu-
mulation of eIF4E within the nucleus (Oh et al., 2007). This finding
first appeared counterintuitive, because this treatment increases
the binding of 4E-BP1 to eIF4E, and biochemical fractionation
experiments had previously led to the conclusion that 4E-BP1
localization is restricted to the cytoplasm (Kim and Chen, 2000;
Kleijn et al., 2002; Zhang et al., 2002). Using a rabbit monoclonal
antibody suitable for immunostaining, we recently showed that
4E-BP1 is present in the nuclei in addition to the cytoplasm of
mammalian cells (Rong et al., 2008). Furthermore, we also
demonstrated that 4E-BPs are required for the nuclear accumu-
lation of eIF4E seen following serum-starvation and/or rapamy-
cin-treatment: conditions that suppress mTOR signaling (Rong
et al., 2008).
The above-described mTOR signaling-modulated and 4E-BP-
dependent alteration in eIF4E subcellular localization forms the
basis for a novel screening approach. In this report, we demon-
strate that cytoplasmic-to-nuclear ratio of eIF4E is a powerful
read-out for mTOR signaling and describe a novel cell-based
chemical genetic screen that analyzes chemical compound
libraries across genetically distinct cell lines. The identification
of novel mTOR pathway inhibitory compounds using our small-
scale screen may provide new insights into the regulation of
mTORC1 versus mTORC2 signaling. It also provides a proof-
of-principle that larger screens using this method are possible,
both in screening for novel mTOR inhibitory compounds and
for counter screens in the search for specific inhibitors of other
kinases, particularly PIKKs.
RESULTS
mTOR Pathway Inhibition Is Required for Nuclear
Accumulation of eIF4E: Dependence on 4E-BPs
To evaluate the potential of eIF4E localization as a specific
marker for mTOR activity we assessed eIF4E localization usingChemistry & Biology 16, 1240–124immunofluorescence after treatment with known PI3K-mTOR
pathway inhibitors (LY294002, wortmannin, rapamycin, and
PI-103) or inhibitors of other signaling pathways: U0126,
SB203580, and JNK inhibitor II (Bain et al., 2007). Screening
for agents that induce a 4E-BP-dependent increase in nuclear
eIF4E was performed using both wild-type murine embryonic
fibroblasts (MEFs) and 4E-BP1, 4E-BP2 double-knockout
(4E-BP1/2 DKO) MEFs, which serve as a negative control.
Nuclear accumulation of eIF4E occurred in wild-type, but not
in 4E-BP1/2 DKO MEFs, treated with PI3K-mTOR pathway
inhibitors (Figure 1 and data not shown). Therefore, inhibition
of mTOR signaling resulting in dephosphorylation of nuclear
4E-BPs is necessary for nuclear accumulation of eIF4E. Impor-
tantly, the inhibitors of other signaling pathways failed to
induce nuclear eIF4E, demonstrating that this readout is spe-
cific to mTOR inhibition. Parallel western blot analyses were per-
formed and demonstrated a strong correlation between inhibi-
tion of mTOR signaling, dephosphorylation of 4E-BP1, and
nuclear accumulation of eIF4E in wild-type but not in 4E-BP1/2
DKO cells (Figure 1). Thus, using immunofluorescence to
study eIF4E localization is a powerful assay for in vivo mTOR
activity.
Primary Screening to Identify Candidate mTOR
Inhibitory Compounds
A screen of 3584 compounds was performed using wild-type
MEFs to test the assay for the identification of potentially novel
mTOR inhibitors. Chemical libraries used include Prestwick
Chemical (1120 structurally diverse marketed drugs), Biomol
(361 natural products), Sigma LOPAC (885 pharmacologically
active organic compounds), and Microsource Discovery (1218
structurally diverse compounds). For each plate of the 96-well
plate-based screen, wells were each treated with one of 80
compounds, while 16 wells were used as negative (dimethyl sulf-
oxide [DMSO]) and positive (rapamycin) controls. eIF4E immu-
nofluorescent intensity was scored within nuclei as defined by
DAPI staining or within a cytoplasmic compartment as defined
by a ring outside the nuclei (Figure 2A). For each plate, rapamy-
cin controls were confirmed to induce nuclear accumulation
of eIF4E (representative images and values are shown in
Figure 2B). Because some apparently toxic compounds dramat-
ically altered cell number, cell morphology, and cell size (Fig-
ure 2C and data not shown), these compounds were eliminated
prior to data analysis (see Experimental Procedures). Some of
these compounds induced significant nuclear accumulation of
eIF4E (see Figure S1A available online), and may warrant further
characterization. Transformed, normalized and standardized
(see Experimental Procedures) cytoplasmic-to-nuclear ratio
was used to identify potential mTOR pathway inhibitory com-
pounds. Forty top-scoring compounds were randomly chosen
and assessed for their ability to induce dephosphorylation of
4E-BP1 as observed by western blot analysis. Notably, only
20% of the compounds induced a significant decrease in
4E-BP1 phosphorylation, emphasizing the need for secondary
screening (Figure S1B).
To directly compare this screening method with immunofluo-
rescence-based monitoring of rpS6 phosphorylation as a read-
out of mTOR signaling, IC50 values were calculated for the
PI3K-mTOR inhibitor LY294002 using both assays and found9, December 24, 2009 ª2009 Elsevier Ltd All rights reserved 1241
Figure 1. Inhibition of mTOR Signaling
Causes 4E-BP-Dependent Nuclear Accu-
mulation of eIF4E
(A) Immunofluorescence analysis of eIF4E locali-
zation in response to treatment with rapamycin
(100 nM), U0126 (20 mM), or PI-103 (2 mM) reveals
that inhibition of the mTOR-PI3K pathway specifi-
cally induces nuclear accumulation of eIF4E in
wild-type and not 4E-BP1/2 DKO cells.
(B) Western blot analysis demonstrates 4E-BP1
dephosphorylation, as evidenced by accelerated
SDS-PAGE mobility and use of phospho-4E-BP1
(Thr37/46) antibody, correlates strongly with
nuclear eIF4E. S6K1 (Thr389) and ERK1/2
(Thr202/Tyr204) serve as controls for inhibitor
function and specificity.
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Figure 2. High Content Screen for Novel
mTOR Pathway Inhibitors Based on eIF4E
Cytoplasmic-to-Nuclear Ratio
(A) Immunofluorescence intensity reflecting eIF4E
levels (red) associated with nuclear (light green)
or cytoplasmic (dark green) compartments as
defined by DAPI staining of DNA (blue).
(B) Representative negative-control (DMSO) and
positive-control (rapamycin) images are shown
with raw data representing cytoplasmic-
to-nuclear eIF4E intensity ratios ([eIF4Ecyto]:
[eIF4Enucl]) that reflect the visible accumulation
of nuclear eIF4E following rapamycin treatment.
(C) Montage of collected images for a repre-
sentative 96-well plate demonstrates homoge-
nous staining, but reveals some compounds
induce gross morphological and cell number alter-
ations.
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mTOR-Dependent eIF4E Translocation Screento be similar (Figure 3). Maximal inhibition of phospho-rpS6
immunofluorescence intensity and maximal induction of nuclear
eIF4E were both observed at a concentration of 50 mM, consis-
tent with previous work demonstrating a greater than 99% inhi-
bition of PI3K at this dose (Vlahos et al., 1994).
Chemical Genetic Screening to Identify mTOR Pathway
Inhibitors
The one hundred top-scoring candidate compounds from the
primary screen above were subjected to a secondary chemical
genetic screen. Because mTOR pathway inhibition-induced
nuclear accumulation of eIF4E is dependent on 4E-BPs (Rong
et al., 2008), 4E-BP1/2 DKO MEFs were used to eliminate
false-positive compounds. As an added control, a homogeneous
clonal population of 4E-BP1/2 DKO MEFs rescued by stable
expression of HA-4E-BP1 was also included in this secondary
screen. Immunofluorescence and western blot characterization
of this cell line confirmed that HA-4E-BP1 expression was homo-
geneous (Figure 4A) and comparable (about one-half) to that ofChemistry & Biology 16, 1240–1249, December 24, 2009 ª4E-BP1 in wild-type cells (Figure 4B).
Importantly, exogenous HA-tagged 4E-
BP1 induced the alteration of eIF4E
subcellular localization phenotype in
response to mTOR signaling perturbation
(Figure 4A).
As expected, the rapamycin control
screening wells displayed significantly
reduced (p < 0.001) eIF4E cytoplasmic-
to-nuclear ratio relative to DMSO con-
trols in wild-type but not 4E-BP1/2 DKO
cells, and this phenotype was rescued
by expression of exogenous HA-4E-BP1
(Figure 4C). Data representing trans-
formed and normalized eIF4E subcellular
localization and cytoplasmic compart-
ment size were used as input parameters
in a principal components analysis (PCA,
see Experimental Procedures). A clear
pattern that separated DMSO and rapa-
mycin controls emerged, andonly ahand-ful of experimental compounds clustered with rapamycin (Fig-
ure 5A). Thus, this method was used to score the compounds,
and the top 15 were identified as putative candidates. The indi-
vidual effects on eIF4E localization across the three cell lines
are displayed for the 15 putative candidates and 42 marginally
scoring compounds (Figure 5B). As an inadvertent internal posi-
tive control, 1 of the 15 identified compounds was rapamycin.
The probability of randomly choosing rapamycin as 1 of 15
top-scoring compounds is less than 0.5%. Other identified
compounds known to impact signaling pathways include phor-
bol esters (12-deoxyphorbol 13-phenylacetate 20-acetate and
12-deoxyphorbol 13-acetate) and a non-phorbol ester PKC acti-
vator, mezerein. It is not surprising that these, as PKC activators,
might reduce 4E-BP1 phosphorylation, because an often-
studied phorbol ester/PKC activator, PMA, shows this activity
(Guan et al., 2007; Hizli et al., 2006). It should be noted, however,
that PMA increases mTOR signaling in some cell lines by
inducing p90RSK-dependent inactivation of the mTOR sup-
pressor, TSC2 (Roux et al., 2004).2009 Elsevier Ltd All rights reserved 1243
Figure 3. Dose-Response Curves for LY294002 Comparing Phospho-rpS6 (Ser235/236) to Cytoplasmic-to-Nuclear eIF4E Intensity Ratio as
Readouts for mTORC1 Signaling
(A) Montage of high content screening images displaying a dose-dependent reduction in phospho-rpS6 immunofluorescence (green) while total eIF4E levels (red)
and nuclear staining (blue) remain constant.
(B) LY294002-induced dephosphorylation of rpS6 and eIF4E nuclear accumulation yield comparable dose-response curves and IC50 values.
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A confirmatory immunofluorescence analysis of cells treated
with putative candidates using rpS6 phosphorylation as a
different marker for mTOR signaling revealed that cells treated
with all but one of the compounds (vinblastine sulfate salt)
displayed dramatically reduced S6 ribosomal protein phosphor-
ylation, while four moderately scoring compounds showed no
significant reduction in S6 phosphorylation (Figure S2A).
Western blot analyses confirmed that five compounds (rapamy-
cin, CP107H6, gingerol, fumagillin, and himbacine) dramatically
inhibit, five compounds (12-deoxyphorbol 13-phenylacetate,
fumonisin B2, e-64-C, ebelactone B, and 12-deoxyphorbol
13-acetate) moderately inhibit, and three compounds (wedelac-
tone, mezerein, and aphidicolin) fail to significantly inhibit
mTORC1 signaling to 4E-BP1 and rpS6 in wild-type MEFs and
in HeLa S3 cells under the conditions used for the screen
(Figure 6A). Further analyses were performed to assess the
specificity of seven promising mTORC1 inhibitory compounds
using ERK1/2 phosphorylation as a read-out for serum-induced
signaling (Figure 6B). Of the tested compounds, ebelactone B,
fumagillin, fumonisin B2, and e-64-c failed to block ERK1/2
phosphorylation. To assess the reproducibility of the findings
reported here, the four compounds able to inhibit mTOR
signaling but not ERK1/2 phosphorylation were purchased,1244 Chemistry & Biology 16, 1240–1249, December 24, 2009 ª2009andwestern blot analysis confirmed that all significantly reduced
phosphorylation of 4E-BP1 and S6K1 (Figure S2B).
DISCUSSION
The development of cell-based assays and high-throughput
screens for inhibitors of mTOR signaling is intensively pursued.
The screen described in this report is particularly powerful and
highly adaptable to high-throughput screening because it utilizes
a readily monitored change in eIF4E subcellular localization and
genetically modified cell lines to measure the in vivo interaction
of eIF4E with 4E-BP1 upon suppression of mTOR signaling.
Although fluorescence resonance energy transfer (FRET) has
been successfully demonstrated in vitro as a means to monitor
the interaction of eIF4E with 4E-BP1 (Kimball and Horetsky,
2001), no in vivo counterpart has been described. The use of
fluorophore-labeled eIF4E could certainly reduce the manpower
required for the eIF4E translocation screen we describe,
although the subcellular localization of fluorophore-tagged
eIF4E may not recapitulate that of endogenous eIF4E (Kedersha
et al., 2005).
This report describes a novel screening method for mTOR
pathway activity and by no means represents a comprehensive
search for novel mTOR inhibitory compounds. Even withinElsevier Ltd All rights reserved
Figure 4. Characterization of the Clonal 4E-BP1
Rescue Cell Line Used for Chemical Genetic
Screening
(A) Immunofluorescence analysis of eIF4E and HA-4E-
BP1 localization in 4E-BP1/2 DKO cells stably expressing
pBABE vector alone or pBABE-HA-4E-BP1 demonstrates
rescue of rapamycin-induced nuclear eIF4E accumula-
tion.
(B) Western blot analysis to assess 4E-BP1 levels and
rapamycin-induced SDS-PAGE mobility shift. Note: HA-
tag retards the apparent SDS-PAGE mobility of 4E-BP1.
(C) Box plots representing transformed and normalized
cytoplasmic-to-nuclear eIF4E intensity values for the
negative (DMSO) and positive (rapamycin) control wells
(n = 16) for each cell line used in the secondary chemical
genetic screen. Rapamycin significantly (p < 0.001)
induced eIF4E nuclear accumulation in wild-type and
HA-4E-BP1 rescued cells but not in 4E-BP1/2 DKO cells.
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mTOR-Dependent eIF4E Translocation Screenthe compound libraries analyzed, mTOR pathway inhibitory
compounds will have been missed. A number of compounds
were eliminated from candidacy for causing grossmorphological
or cell number alterations at a concentration of 50 mM. It is
possible that some of these could function as excellent, highly
potent mTOR pathway inhibitors at lower concentrations.
Indeed, the PI3K inhibitors (LY294002 and wortmannin) were
both present in the compound libraries screened, but only wort-
mannin was carried on to the secondary screen. Ultimately,
however, both were removed from candidacy due to the afore-
mentioned cell number and cytoplasmic compartment area
filters, presumably due to toxicity at the chosen concentration
and treatment time. It is noteworthy, however, that rapamycin
even at 50 mM (2000 times the standard concentration) was iden-
tified as one of the 15 best scoring compounds in this screen.
Presumably, this is a reflection of the nontoxicity of this natural
product across a broad range of concentrations. Indeed, the
bulk of compounds identified as inducing ‘‘rapamycin-like’’
changes in eIF4E subcellular localization in the secondary,
chemical genetic screen described above are also natural
products.Chemistry & Biology 16, 1240–1249, December 24,Although none of the identified compounds
was comparable to rapamycin in its ability to
specifically inhibit mTOR signaling across
a broad range of concentrations, multiple
compounds did significantly inhibit mTORC1
signaling under the conditions used for the
screen. Although the scope of this study was
not aimed at determining the molecular link
between each compound and mTOR signaling,
known targets of four promising mTORC1
pathway inhibitory compounds identified here
merit discussion. Ebelactone B, for example, is
a known inhibitor of membrane esterases that
may regulate PP2A function (Kowluru et al.,
1996; Tan and Rando, 1992). It is also note-
worthy that the known PIKK inhibitors wortman-
nin and LY294002 are also lactones (Konaklieva
and Plotkin, 2005), and the lactone oxygen of
wortmannin appears to be crucial for competi-tion with ATP (Walker et al., 2000). Fumagillin is known to inhibit
methionine aminopeptidase 2 (MetAP2) (Griffith et al., 1997),
a potential Ras GTPase activating protein (Xu et al., 1990). Iden-
tification of fumagillin as an mTOR pathway inhibitory agent
suggestsMetAP2 activity may feed intomTOR signaling. Indeed,
MetAP2 is upregulated in neurofibromatosis 1 (Nf1)–associated
glioma, which is characterized by hyperactive mTOR signaling
(Dasgupta et al., 2005a), and proliferation of Nf1/ cells is
blocked with fumagillin or rapamycin (Dasgupta et al., 2005b).
Fumonisin B2, an inhibitor of sphinganine N-acyltransferase
(ceramide synthase) (Wang et al., 1991), was also identified
and may suggest a link between sphingolipid metabolism and
mTOR signaling. Finally, the calpain inhibitor E-64-c also
reduced mTOR signaling, which is unexpected in light of pre-
vious evidence that calpain itself is inhibitory to Akt and mTOR
signaling (Smith and Dodd, 2007).
SIGNIFICANCE
The mammalian target of rapamycin (mTOR) has proven
to be a therapeutically beneficial drug target due to its2009 ª2009 Elsevier Ltd All rights reserved 1245
Figure 5. Putative Candidate mTORC1 Pathway
Inhibitors Identified by Chemical Genetic
Screening
(A) Principal components analysis of eIF4E localization
and cytoplasmic compartment size in response to candi-
date compounds across the three cell lines. Compounds
(c) cluster either with rapamycin (RAP) or with DMSO
controls primarily based on component 1 (x axis).
(B) Heat map of compounds with a transformed and
normalized cytoplasmic-to-nuclear eIF4E intensity ratio
< 0 in WT cells. Shown is score from PCA component 1
(as a gray scale with high score indicated by black) for
compounds clustered based on eIF4E cytoplasmic-to-
nuclear localization as indicated and cytoplasmic
compartment area (data not shown) across the three cell
lines. Green indicates a reduced cytoplasmic-to-nuclear
eIF4E intensity ratio, while red indicates opposite effect,
with black representing an intermediate effect.
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and extracellular signals to modulate cellular growth and
proliferation. In this report we provide strong proof-of-
principle data illustrating the power and usefulness of a
novel cell-based assay for compounds that impact mTOR
signaling. The readout for this screen is the nuclear accumu-
lation of the mRNA 50 cap binding protein eIF4E, which
we demonstrate to occur specifically upon inhibition of
mTOR-dependent phosphorylation of 4E-BPs. This chemical
genetic screen makes use of genetically modified cell lines,1246 Chemistry & Biology 16, 1240–1249, December 24, 2009 ª2009 Elsevier Ltd All rthus reducing the possibility of false posi-
tives, including autofluorescent compounds.
Given the ongoing efforts toward develop-
ment of mTOR and PIKK inhibitors, this
screen can directly be used with much larger
chemical libraries to identify novel classes of
mTOR pathway inhibitory molecules. The
compounds identified in our small-scale
screen as specifically inhibiting mTORC1
signaling to 4E-BP1 and S6K1 provide new
information regarding the regulation of
mTOR signaling and may form the basis of
novel strategies to target this important regu-
lator of cell growth and proliferation.
EXPERIMENTAL PROCEDURES
The wild-type and 4E-BP1/; 4E-BP2/ MEFs have
been previously described, as has the pBABE-puro-HA-
4E-BP1 rescue cell line (Rong et al., 2008). The subcellular
localization of eIF4E was monitored by indirect immuno-
fluorescence (anti-mouse IgG Alexa647, 1:200, Invitrogen)
colocalization with DAPI (200 ng/ml)-stained nuclei,
wherein cells were washed with cold phosphate-buffered
saline (PBS), prior to fixation with formaldehyde (3.7% in
PBS, 37C, 10 min) and permeabilization with methanol
(100%, 20C) followed by blocking in bovine serum
albumin (BSA) (2% in PBS) and overnight incubation with
eIF4E mAb (1:400 in 2% BSA, BD Transduction Labs).
Commercially available compound libraries (Prestwick,
Biomol, MicroSource Discovery, and Sigma LOPAC)
were used for screening at 50 mM for 5 hr. This and similardrug concentrations have previously been shown to be optimal for inducing
nuclear accumulation of the transcription factor FOXO1A using high content
screening (Haney, 2008; Kau et al., 2003), and hence was chosen as the start-
ing concentration for subsequent screening experiments. Additional
compounds including PI-103, JNK inhibitor II (EMD Biosciences), LY294002,
Wortmannin, U0126 (Sigma-Aldrich), Rapamycin, Swainsonine, Fumagillin,
E-64-c, Fumonisin B2, and Ebelactone B (Biomol) were purchased separately
for controls and validation screening.
For all screening experiments, cytoplasmic-to-nuclear eIF4E intensity ratios
(MetaXpress Translocation-Enhanced) for each well of 96-well plates were
collected, as were compartment size and cell number values. All data analysis
was performed in R (www.r-project.org). For both the primary and theights reserved
Figure 6. Western Blot-Based Characterization of Top-Scoring
Compounds
(A) The majority of top-scoring compounds (50 mM, 5 hr) significantly reduce
4E-BP1andrpS6phosphorylation inwild-typeMEFs (upper)and inHeLaS3cells
(lower). The phorbol esters 12-deoxyphorbol 13-phenylacetate (12-DP 13-PA)
and 12-deoxyphorbol 13-acetate (12-DP 13-A) induce intermediate effects.
(B) Western blot assessment of the impact of these compounds (2 mM, 1 hr) on
serum-stimulated (20%, 30 min) ERK phosphorylation.
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in compartment size (<75%mean) or cell number (<25%mean)were discarded
and did not participate in data transformation and normalization. For the first
screen, cytoplasmic-to-nuclear eIF4E intensity ratios were log2 transformed
and subjected to normalization plate by plate after removing positive and
negative controls using the trimmed polish approach, which is a modification
of the median polish approach using the mean instead of the median, after
removing top and bottom 10% (per row or column). This approach identified
and removed both row and column bias. The data were further standardized
using the median absolute deviation per plate. This transformed, normalized,
and standardized data set was used to create a ranking of all compounds,
and the immunofluorescence images associated with top 150 scoring
compounds (approximately corresponding to standardized values < 2)
were subjected to visual inspection to eliminate compounds generating gross
morphological alterations. For the secondary screen, a separate data analysis
approach was used, because the approach described for the first screen
relies on the presence of a limited set of hits per plate, whereas the second
round screening could contain more hits that may be artificially removed by
the trimmed polish approach. The compartment size and the cytoplasmic-to-
nuclear eIF4E intensity ratios were log2 transformed and centered (mean 0)
per plate. The resulting data set (three cell types, both cytoplasmic-to-nuclear
eIF4E intensity ratios, and cytoplasmic compartment area) was used in a PCA.
Compounds showing a transformed normalized cytoplasmic-to-nuclear
eIF4E intensity ratio < 0 in the wild-type cell line were subjected to hierarchical
clustering while indicating the score from the PCA analysis.
Western blot (phospho-S6K1 T389, phospho-ERK1/2 T202/Y204, phospho-
rpS6 S240/244, 4E-BP1, phospho-4E-BP1 T37/46 ,and phospho-4E-BP1
S65) and immunostaining analyses (phospho-rpS6 S235/6) were performed
according to the manufacturer’s (Cell Signaling Technology) recommended
protocols. 4E-BP1 phosphorylation was assessed using phospho-specific
antibodies or by calculating relative band intensities (ImageJ) for hyperphos-
phorylated (upper band) and hypophosphorylated (lower band). Alexa488
and Alexa647 conjugated secondary antibodies (Invitrogen) were used for indi-
rect immunofluorescence. Confocal images were obtained using a 63X objec-
tive of a Zeiss LSM 510 confocal microscope. Additional antibodies used for
immunostaining experiments were HA-tag (16B12) mAb (Covance), and
eIF4E rabbit mAb (Cell Signaling Technology).Chemistry & Biology 16, 1240–124SUPPLEMENTAL DATA
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